Caricamento...
Busulfan Pharmacokinetics in ADA SCID Gene Therapy
The pharmacokinetics of low dose busulfan (BU) were investigated as a non-myeloablative conditioning regimen for autologous gene therapy (GT) in pediatric subjects with adenosine deaminase-deficient severe combined immunodeficiency (ADA SCID). In three successive clinical trials, which included eith...
Salvato in:
| Pubblicato in: | Biol Blood Marrow Transplant |
|---|---|
| Autori principali: | , , , , , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
2020
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7529956/ https://ncbi.nlm.nih.gov/pubmed/32653625 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bbmt.2020.07.004 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|